DxWound

Doctor tending to foot wound

DxWound Helps Wound Care Clinicians Turn Data into Decisions

DxWound harnesses the precision and sensitivity of genomic technology to provide a consolidated solution geared specifically to wound care providers.

Discover the benefits of DNA-based diagnostic testing to help clinicians rapidly determine course of therapy for patients with suspected wound infections.

Doctor tending to patient's wound

Using tiny amounts of microbial DNA as starting material, DxWound provides accurate, sensitive detection of an array of microbes, including aerobic/anaerobic bacteria and fungi, plus antibiotic resistance genes – all delivered in a single actionable report typically within one business day.*

DxWound equips clinicians with comprehensive information about the wound microbiome that may help them effectively and rapidly navigate important treatment decisions for their patients, including:

  • Selecting appropriate antibiotic when current therapy fails
  • Treatment planning to de-escalate or narrow broad spectrum therapy
  • Determining appropriate therapy for suspected polymicrobial infections
  • Identifying potential for antibiotic resistance in suspected infections
  • Evaluating treatment options for stagnant, non-healing wounds
  • Selecting appropriate therapy for suspected anaerobic or fungal infections

Discover the next era of diagnostic testing that may help alleviate some of the trial-and-error of managing wound infections. Rapid, comprehensive and actionable testing means clinicians can spend more time focused on healing their patient’s wound– and less time trying to resolve infections.

3d Rendering of Bacteria

aerobic & anaerobic bacteria

3d Rendering of Fungi

Fungi

3d Rendering of DNA

antibiotic resistance genes

Moving Beyond Just the Usual Microbial Suspects with Molecular Diagnostics

The wound microbiome is highly diverse and can be populated with microbial species that are not routinely tested for using traditional laboratory methods.1

25% of chronic wounds

of chronic wounds of various etiologies can be populated by anaerobic bacteria, including strict anaerobes,1 and fungal species that are known opportunistic pathogens2

The diversity of the wound microbiome may make it challenging to empirically select antibiotics that effectively target the causative agent.1

A recent study demonstrated that initial treatment failure was experienced in as many as3

16.6% of acute SSTIs,

16.6% of acute SSTIs result in initial treatment failure

26.7% of surgical site infections, and

26.7% of surgical site infections result in initial treatment failure

34.1% of chronic or ulcerative infections

34.1% of chronic or ulcerative infections result in initial treatment failure

Effectively targeting antimicrobial therapy to the causative agent, especially within 48 hours, may reduce risk for treatment failure4, and poor patient outcomes such as extended hospital LOS, and increased mortality5.

Targeting antimicrobial therapy within 48 hours

DxWound Offers Key Features that May Help Clinicians Rapidly Deliver Targeted, Effective Therapy

Rapid. Next business day results can help accelerate clinical decision making for patients.

  • Easy online test ordering and secure access to patient results typically within next business day*
  • Fast and simple specimen collection process means minimal training for clinical staff

Comprehensive. Accuracy and precision of DNA-based detections allows clinicians to evaluate more than the usual suspects.

  • Simultaneous detection of clinically relevant aerobes, anaerobes and fungal species plus genes associated with antibiotic resistance
  • Transport solution “freezes” wound microbiome at time of collection by killing microbes while preserving their DNA

Actionable. Transform diagnostic test results into decisions with user-friendly, actionable reporting.

  • Consolidated report allows clinicians to determine at a glance if potential pathogens detected
  • Highlights CDC alerts for pathogens of concern and potential antibiotic resistance threats
Doctor happy with DxWound

Partner with CogenDx, Impact Your Patient’s Life

Learn more about how DxWound can provide clinicians with a rapid, comprehensive and actionable diagnostic solution

Get Started

© 2017 Millennium Health, LLC - CogenDx is a brand name under Millennium Health. Privacy Policy

*from specimen receipt at laboratory

The CogenDx logo is a service mark or registered service mark of Millennium Health, LLC or its subsidiaries in the United States and other Countries. All other trademarks used herein are the property of their respective owners

These clinical laboratory developed tests (LDTs) were developed and their performance characteristics determined by Millennium Health, LLC and have not been cleared or approved by the US Food and Drug Administration (FDA). These LDTs are clinical tests and their results should be used with other clinical observations and diagnostic findings for patient case management. Millennium Health, LLC maintains certification in accordance with Clinical Laboratory Improvement Amendments of 1988 and is accredited by the College of American Pathologists.

References
  1. Wolcott, R. D., et al. Analysis of the chronic wound microbiota of 2,963 patients by 16S rDNA pyrosequencing. Wound Rep and Reg, 2016. 24: 163–174.
  2. Dowd, S.E., et al. Survey of fungi and yeast in polymicrobial infections in chronic wounds. J Wound Care. 2010. 20(1): 40-47.
  1. Berger et al., Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect 2013, 14(3):304-312
  2. Amin, A.N., et al., Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin Proc. 2014. 89(10): 1436-51.
  1. Pogue, J.M. et al. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Micro Infec, 2015. 21(4): 302 – 312.